Aptinyx
Evanston
Illinois
United States
128 articles about Aptinyx
-
Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
12/7/2017
The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.
-
Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as CCO
12/7/2017
Andy's experience will be instrumental in achieving and leveraging anticipated milestones,.
-
Aptinyx Initiates Phase II Clinical Studies Evaluating NYX-2925 In Two Chronic Pain Conditions
8/1/2017
-
Aptinyx Chief Scientific Officer Joseph Moskal, Ph.D. Named Fellow By National Academy Of Inventors And The American Institute For Medical And Biological Engineering
2/21/2017
-
Aptinyx Awarded Up To $2.85 Million In NIH Grants To Research NMDA Receptor Modulation For The Treatment Of Neuropathic Pain And Age-Related Cognitive Decline
11/11/2016
-
Aptinyx Receives FDA Fast Track Designation For Development Of NYX-2925 As Treatment For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
9/13/2016
-
Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925
7/13/2016
-
Naurex Spinout Aptinyx Banks $65 Million Series A to Advance Therapies for Neurological Disorders
5/10/2016